Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
45.27
+2.30 (5.35%)
At close: May 12, 2025, 4:00 PM
44.00
-1.27 (-2.81%)
After-hours: May 12, 2025, 6:09 PM EDT
Protagonist Therapeutics Revenue
Protagonist Therapeutics had revenue of $28.32M in the quarter ending March 31, 2025, a decrease of -88.89%. This brings the company's revenue in the last twelve months to $207.80M, down -34.02% year-over-year. In the year 2024, Protagonist Therapeutics had annual revenue of $434.43M with 624.06% growth.
Revenue (ttm)
$207.80M
Revenue Growth
-34.02%
P/S Ratio
13.53
Revenue / Employee
$1,649,214
Employees
126
Market Cap
2.81B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 434.43M | 374.43M | 624.06% |
Dec 31, 2023 | 60.00M | 33.42M | 125.73% |
Dec 31, 2022 | 26.58M | -776.00K | -2.84% |
Dec 31, 2021 | 27.36M | -1.27M | -4.44% |
Dec 31, 2020 | 28.63M | 28.40M | 12,293.07% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
PTGX News
- 6 days ago - Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update - Accesswire
- 19 days ago - Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025 - Accesswire
- 26 days ago - Protagonist Therapeutics Reports Granting of Inducement Award - Accesswire
- 7 weeks ago - Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025 - Accesswire
- 2 months ago - Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It - Seeking Alpha
- 2 months ago - Why Is Protagonist Therapeutics Stock Trading Higher On Monday? - Benzinga
- 2 months ago - Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera - Business Wire
- 2 months ago - Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - Accesswire